Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting

- Exploratory endpoint analyses demonstrated Allocetra’s potential therapeutic effect in resolving cytokine storms in patients with heterogenous pathologies

Nes Ziona, Israel, May 28, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that new analyses from its recently completed Phase Ib clinical trial of Allocetra^TM in patients with sepsis will be presented as part of an oral presentation at the International Society for Cellular Therapy (ISCT) 2020 Paris-Virtual Annual Meeting at a plenary satellite entitled “Moving ahead at full speed: Immune-Mediated Therapeutics”. The presentation will include  new exploratory endpoint analyses that demonstrated the potential of Allocetra^TM to resolve cytokine storms with heterogenous underlying pathologies, as well as previously disclosed safety and efficacy data. ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, comprising more than 1700 cell and gene therapy experts across five geographic regions and representation from over 60 countries.

Enlivex’s newly presented data tracked the levels of 30+ immune modulators in patients with sepsis before and after Allocetra^TM treatment. Abnormal levels of each class of immune modulator (e.g. pro-inflammatory cytokines, anti-inflammatory cytokines, chemokines, etc.) were observed in sepsis patients prior to treatment. Following treatment, patients with dysregulated immune modulators of all classes returned to, or trended towards, levels consistent with immune homeostasis, despite the heterogeneous baseline in cytokine storm profile of immune modulators – including IL-6, TNFα, MCP-1, IL-10 and many others – that were dysregulated differently across patients.

“These new data show that patients with sepsis experience cytokine storms that are highly heterogenous and characterized by dysregulation across multiple immune modulation subsystems,” said Prof. Dror Mevorach, M.D., Chief Scientific and Medical Officer of Enlivex. “This is significant because we believe the data hightlight the unmet need for sepsis treatments that simultaneously target each dysregulated immune subsystem, rather than a single cytokine or biological pathway. The data presented at the ISCT meeting demonstrated that Allocetra^TM has the potential to effectively address this unmet need and further supports the safety and efficacy profile of our lead product candidate in severe sepsis patients. Additionally, we believe that these results also support the use of Allocetra^TM in other cytokine storm conditions such as those resulting from COVID19.”